Joseph A. Sparano, MD
New York, New York
Ezra Greenspan MD Professor in Clinical Cancer Therapeutics
Chief, Division of Hematology/Oncology
Vice-Chair, ECOG-ACRIN Cancer Research Group
Icahn School of Medicine at Mt. Sinai
New York, New York
To improve treatment outcomes and reduce the risk of breast cancer recurrence by identifying biomarkers to inform treatment decisions, as well as to advance the understanding of invasive lobular carcinomas.
Working under the auspices of the Coalition of Cancer Cooperative Groups and ECOG-ACRIN Breast Committee, BCRF investigator, Dr. Joseph Sparano is leading efforts to advance the clinical management of breast cancer by utilizing resources collected as part of ongoing clinical trials to identify biomarkers that can better inform treatment decisions. Blood and tissue samples from breast cancer patients who take part in clinical trials are a valuable resource for researchers. They reveal details about the nature of the disease and can also be used to discover biomarkers that help inform personalize treatments and reduce side effects. Dr. Sparano oversees ongoing data analysis of samples from the Late-Relapse Repository, also established with BCRF support, and ECON-ACRIN trials to identify and validate markers from patient tissue and blood to improve personalized treatment approaches and outcomes for breast cancer patients. Part of his ongoing work is the characterization and evaluation of invasive lobular cancer in ECOG-ACRIN Phase III breast cancer trials. Invasive lobular breast cancer (ILC) is the second most prevalent type of the disease, arising in the milk-producing glands of the breast. Dr. Sparano's research in ILC is essential to understand the many subtypes of breast cancer. He hopes these studies will provide much-needed insight into this understudied form of breast cancer.
Results from the ECON-ACRIN trials have shown that there are genetic markers that may indicate a patient is at higher risk of neuropathy when treated with chemotherapy. In addition, a recent discovery from the TAILORx trial validated a gene-based test to predict which patients can safely forego chemotherapy after hormone treatment for breast cancer. From another ECOG-ACRIN study, Dr. Sparano and his colleagues determined that circulating tumor cells (CTCs)—tumor cells that have escaped the tumor and entered the circulation—in the blood of patients with early-stage breast cancer was associated with an 18. 3 percent increased risk of breast cancer recurrence.
In addition to continuing his current studies, Dr. Sparano and his team will analyze tumor samples obtained from patients who experienced a late relapse (5 or more years after treatment) of breast cancer to evaluate biomarkers that can help identify patients with early-stage breast cancer who are at risk of recurrence. Efforts in the next year will also include analyzing data from several ECOG-ACRIN breast cancer treatment trials including studies in patients with metastatic and triple-negative breast cancers, assessing the best mammographic screening modality for healthy women, and identifying patients at risk of aromatase inhibitor-induced musculoskeletal symptoms.
Dr. Joseph Sparano, MD is the Ezra Greenspan MD Professor in Clinical Cancer Therapeutics and the Chief of the Division of Hematology/Oncology at the Icahn School of Medicine at Mt. Sinai. He is the Deputy Director of the Tisch Cancer Institute also at the Icahn School of Medicine at Mt. Sinai in New York, New York. He also serves as Vice Chair of ECOG-ACRIN and Vice-Chairman of the AIDS Malignancy Consortium.
Dr. Sparano's research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and therapeutic applications of genomic profiling in cancer. He is the chair of the TAILORx clinical trial in breast cancer, an NCI-sponsored trial designed that is integrating multi-parameter gene expression profiling in clinical practice (http://www.cancer.gov/clinicaltrials/noteworthy-trials/tailorx).
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.